CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-16 | Vakiener Victoria Director | Sale 10b5-1 | −8,994 | $21.91 | $197K | 21,211 |
| 2024-07-02 | Oliver Tracie Chief Commercial Officer | Sale 10b5-1 | −9,394 | $25.28 | $237K | 127,107 |
| 2024-05-02 | Vakiener Victoria Director | Sale 10b5-1 | −1,799 | $23.31 | $42K | 30,205 |
| 2024-04-01 | Hamilton James C Chief Discovery/Trans Medicine | Sale | −6,000 | $28.03 | $168K | 204,851 |
| 2024-03-20 | Lu Hongbo Director | Purchase | +1,000 | $27.50 | $28K | 33,680 |
| 2024-03-19 | Lu Hongbo Director | Purchase | +1,000 | $28.00 | $28K | 32,680 |
| 2024-03-18 | Lu Hongbo Director | Purchase | +1,000 | $27.49 | $27K | 31,680 |
| 2024-03-06 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −40,000 | $35.19 | $1.4M | 400,600 |
| 2024-01-31 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +57,499 | $14.54 | $836K | 3,772,547 |
| 2024-01-31 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −37,769 | $32.16 | $1.2M | 3,734,778 |
| 2024-01-31 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −19,730 | $32.71 | $645K | 3,715,048 |
| 2024-01-31 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −57,499 | 351,726 | ||
| 2024-01-12 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −4,238 | $36.47 | $155K | 214,553 |
| 2024-01-12 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −3,702 | $37.37 | $138K | 210,851 |
| 2024-01-11 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −1,811 | $37.76 | $68K | 130,811 |
| 2024-01-11 | GIVEN DOUGLAS B Director | Sale 10b5-1 | −1,100 | $38.55 | $42K | 129,711 |
| 2024-01-11 | Waddill William D. Director | Sale 10b5-1 | −2,634 | $37.81 | $100K | 49,170 |
| 2024-01-11 | Waddill William D. Director | Sale 10b5-1 | −1,300 | $38.59 | $50K | 47,870 |
| 2024-01-11 | Ferrari Mauro Director | Sale 10b5-1 | −2,147 | $37.80 | $81K | 61,778 |
| 2024-01-11 | Ferrari Mauro Director | Sale 10b5-1 | −1,000 | $38.63 | $39K | 60,778 |
Page 8 of 38 · 752 trades